TY - JOUR
T1 - Artificial Intelligence-Assisted Diagnostic Cytology and Genomic Testing for Hematologic Disorders
AU - Gedefaw, Lealem
AU - Liu, Chia Fei
AU - Ip, Rosalina Ka Ling
AU - Tse, Hing-Fung
AU - Yeung, Ho Yin Martin
AU - Yip, Shea Ping
AU - Huang, Chien-Ling
N1 - Funding Information:
This study is supported by the General Research Fund (no. 15106422 to C.-L.H. and S.P.Y.) from the Research Grants Council, and the Health and Medical Research Fund Commissioned Re-search on COVID-19 (no. COVID1903007).
Publisher Copyright:
© 2023 by the authors.
PY - 2023/6/30
Y1 - 2023/6/30
N2 - Artificial intelligence (AI) is a rapidly evolving field of computer science that involves the development of computational programs that can mimic human intelligence. In particular, machine learning and deep learning models have enabled the identification and grouping of patterns within data, leading to the development of AI systems that have been applied in various areas of hematology, including digital pathology, alpha thalassemia patient screening, cytogenetics, immunophenotyping, and sequencing. These AI-assisted methods have shown promise in improving diagnostic accuracy and efficiency, identifying novel biomarkers, and predicting treatment outcomes. However, limitations such as limited databases, lack of validation and standardization, systematic errors, and bias prevent AI from completely replacing manual diagnosis in hematology. In addition, the processing of large amounts of patient data and personal information by AI poses potential data privacy issues, necessitating the development of regulations to evaluate AI systems and address ethical concerns in clinical AI systems. Nonetheless, with continued research and development, AI has the potential to revolutionize the field of hematology and improve patient outcomes. To fully realize this potential, however, the challenges facing AI in hematology must be addressed and overcome.
AB - Artificial intelligence (AI) is a rapidly evolving field of computer science that involves the development of computational programs that can mimic human intelligence. In particular, machine learning and deep learning models have enabled the identification and grouping of patterns within data, leading to the development of AI systems that have been applied in various areas of hematology, including digital pathology, alpha thalassemia patient screening, cytogenetics, immunophenotyping, and sequencing. These AI-assisted methods have shown promise in improving diagnostic accuracy and efficiency, identifying novel biomarkers, and predicting treatment outcomes. However, limitations such as limited databases, lack of validation and standardization, systematic errors, and bias prevent AI from completely replacing manual diagnosis in hematology. In addition, the processing of large amounts of patient data and personal information by AI poses potential data privacy issues, necessitating the development of regulations to evaluate AI systems and address ethical concerns in clinical AI systems. Nonetheless, with continued research and development, AI has the potential to revolutionize the field of hematology and improve patient outcomes. To fully realize this potential, however, the challenges facing AI in hematology must be addressed and overcome.
KW - artificial intelligence
KW - hematologic disorders
KW - diagnostic cytology
KW - genomic testing
KW - machine learning
UR - https://www.scopus.com/pages/publications/85164844947
U2 - 10.3390/cells12131755
DO - 10.3390/cells12131755
M3 - Review article
SN - 2073-4409
VL - 12
JO - Cells
JF - Cells
IS - 13
M1 - 1755
ER -